Owing to the strong association of non-alcoholic fatty liver disease with obesity and cardiometabolic disease, in 2020 experts controversially proposed to rename this condition as ‘metabolic associated fatty liver disease’. Additional studies have elucidated new genetic and dietary modifiers of this disease. This knowledge is essential to improve diagnosis, risk-stratification and treatment.
Key advances
-
The largest genome-wide association study performed on liver biopsy samples to date confirmed a role for a variant in the PNPLA3 locus in the complete histological spectrum of non-alcoholic fatty liver disease and implicated PYGO1, a gene involved in hepatocellular development, in this condition3.
-
Preliminary data show that a machine learning algorithm efficiently quantified steatosis in population scale MRI data and helped define the role of genetic variants and environmental modifiers in hepatic steatosis, including a role for alcohol metabolism5.
-
Fructose metabolism within the small intestine regulates the delivery of fructose to the liver and the distal colon, which affects hepatic lipogenesis and steatosis8,9,10.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Eslam, M. et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158, 1999–2014 (2020).
Younossi, Z. M. et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology https://doi.org/10.1002/hep.31420 (2020).
Anstee, Q. M. et al. Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. J. Hepatol. 73, 505–515 (2020).
Zhu, C., Tabas, I., Schwabe, R. F. & Pajvani, U. B. Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis. Nat. Rev. Gastroenterol. Hepatol. https://doi.org/10.1038/s41575-020-00365-6 (2020).
Haas, M. E. et al. Machine learning enables new insights into clinical significance of and genetic contributions to liver fat accumulation. Preprint at medRxiv https://doi.org/10.1101/2020.09.03.20187195 (2020).
Hannou, S. A., Haslam, D. E., McKeown, N. M. & Herman, M. A. Fructose metabolism and metabolic disease. J. Clin. Invest. 128, 545–555 (2018).
Jensen, T. et al. Fructose and sugar: a major mediator of non-alcoholic fatty liver disease. J. Hepatol. 68, 1063–1075 (2018).
Andres-Hernando, A. et al. Deletion of fructokinase in the liver or in the intestine reveals differential effects on sugar-induced metabolic dysfunction. Cell Metab. 32, 117–127 (2020).
Jang, C. et al. The small intestine shields the liver from fructose-induced steatosis. Nat. Metab. 2, 586–593 (2020).
Zhao, S. et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 579, 586–591 (2020).
Acknowledgements
The author acknowledges the support of NIH R01-DK100425 and NIH R01-DK121710.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Herman, M.A. Metabolic liver disease — what’s in a name?. Nat Rev Endocrinol 17, 79–80 (2021). https://doi.org/10.1038/s41574-020-00452-3
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-020-00452-3
